Related Experiment Video

Updated: Jun 22, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.5K

ASAH1 facilitates TNBC by DUSP5 suppression-driven activation of MAP kinase pathway and represents a therapeutic

Kiran Kumar Reddi1, Suresh Chava1, Siva Chander Chabattula1

  • 1Department of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, AL, USA.

Cell Death & Disease
|June 26, 2024
PubMed

Insights

N-acylsphingosine amidohydrolase 1 (ASAH1) drives triple-negative breast cancer (TNBC) growth. Inhibiting ASAH1 and the MAPK pathway offers a potential new therapy for TNBC.

Area of Science:

  • Oncology
  • Biochemistry
  • Molecular Biology

Background:

  • Triple-negative breast cancer (TNBC) presents aggressive characteristics, including metastasis and therapy resistance, leading to higher mortality rates.
  • Limited targeted therapies exist for TNBC, necessitating research into novel therapeutic strategies.
  • Understanding the molecular drivers of TNBC growth and progression is crucial for developing effective treatments.

Purpose of the Study:

  • To identify and characterize key factors involved in triple-negative breast cancer (TNBC) growth and progression.
  • To investigate the role of N-acylsphingosine amidohydrolase 1 (ASAH1) in TNBC.
  • To explore potential therapeutic strategies targeting ASAH1 and associated signaling pathways in TNBC.

Main Methods:

  • Overexpression analysis of N-acylsphingosine amidohydrolase 1 (ASAH1) in TNBC cells.
  • Genetic knockdown and pharmacological inhibition of ASAH1.
  • Investigation of ASAH1 regulation by p53 and PI3K-AKT signaling pathways.
  • Assessment of ASAH1 inhibition effects on dual-specificity phosphatase 5 (DUSP5) and mitogen-activated protein kinase (MAPK) pathways.
  • Pharmacological cotargeting of ASAH1 and MAPK pathways.

Main Results:

  • N-acylsphingosine amidohydrolase 1 (ASAH1) is overexpressed in triple-negative breast cancer (TNBC) cells and regulated by p53 and PI3K-AKT pathways.
  • Genetic or pharmacological inhibition of ASAH1 significantly suppresses TNBC growth and progression.
  • ASAH1 inhibition leads to increased DUSP5 expression, subsequently suppressing the MAPK pathway.
  • Combined inhibition of ASAH1 and MAPK pathways demonstrates potent anti-tumor effects in TNBC models.

Conclusions:

  • N-acylsphingosine amidohydrolase 1 (ASAH1) plays a critical role in driving triple-negative breast cancer (TNBC) proliferation and progression.
  • Targeting ASAH1 represents a promising therapeutic avenue for TNBC.
  • Dual targeting of the ASAH1 and MAPK pathways offers a novel and potentially effective therapeutic strategy for TNBC treatment.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.3K

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K